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Aβ oligomer-induced neurotoxicity has become an important area of therapeutic development in 
treating Alzheimer’s disease. Platelet-derived growth factor (PDGF) has been shown to be able to 
protect neurons against several neuronal insults such as ischemia and HIV1 toxin induced 
cytotoxicity. These neuroprotective effects correlate well with our previous results that demonstrate 
the neuroprotective effects of PDGF-BB, one of the PDGF receptor ligand subtypes, against NR2B 
containing NMDA receptor induced excitotoxicity, a possible underlying cause of Aβ oligomer 
induced synaptic dysfunction and neuronal death. This project examines the neuroprotective effect of 
PDGF-BB against Aβ1-42 oligomer induced cytotoxicity in both SH-SY5Y cells and primary 
hippocampal neurons. Cell viability was monitored by MTT assay and the affected signaling 
pathways were examined using pharmacological methods and Western blotting. The results 
demonstrated that Aβ1-42 oligomer elicited a dose-dependent toxicity with a sign of saturation at 
higher dosages, PDGF-BB failed to protect neurons against Aβ1-42 oligomer induced cytotoxicity. In 
contrast, Aβ1-42 oligomers strongly inhibit PDGF-BB induced mitogenesis in both SH-SY5Y cells and 
primary neurons. Further investigation using Western blotting to measure PDGF receptor expression 
and phosphorylation in SH-SY5Y cells showed that Aβ1-42 oligomer can inhibit PDGF-BB induced 
phosphorylation of PDGF β-receptor on Tyr1021, a site that is crucial for PLCγ mediated 
mitogenesis. These findings not only explained the poor neuroprotective effect elicited by PDGF-BB 
against Aβ1-42 oligomers, but also led to a novel hypothesis that Aβ1-42 oligomer may interfere with 
neurotrophic factor induced neuronal survival, either selectively or perhaps globally. Further 
exploration on this hypothesis will be able to shed light on this potentially novel mechanism of 
pathogenesis in Alzheimer’s disease. 
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Chapter I  
Introduction 
 
1.1. Alzheimer’s disease (AD) and the two pathological hallmarks 
Alzheimer’s disease (AD) is a progressively developing neurodegenerative disorder of the brain. Over 
time, patients may lose memories, physical coordination, and eventually die on average within 7 years 
after the diagnosis
1
. As more baby boomers are reaching age of 65, AD will represent a greater and 
greater economic and social burden to the society, making the search for efficient treatment, 
especially at its early stage, an urgent medical research objective. 
At the cellular level, the disease is characterized by synaptic dysfunction and neuronal loss. While the 
etiology of AD remains unknown, senile plaques and neurofibrillary tangles (NFTs) are typically 
found in the post-mortem brains and are the two well-accepted hallmarks of AD
2
. Senile plaques are 
primarily extracellular deposits of β-amyloid (Aβ) peptides and NFTs are mainly intracellular 
deposits of hyperphosphorylated tau, a microtubule-associated protein.  
Aβ is produced in all normal brains through a proteolytic process on a membrane-bound protein, 
amyloid precursor protein (APP). APP can be either cleaved by combination of α- and γ-secretases or 
β- and γ-secretases. The latter combination leads to the production of Aβ and therefore is classified as 
the amyloidogenic pathway: Aβ is misfolded and aggregates in β sheets to form senile plaques
3
. 
There are various forms of Aβ found in senile plaques
4
, but it is believed that the longer and more 
hydrophobic form of Aβ, Aβ1-42, is the most toxic and is responsible for the early stage of senile 
plaque formation
4, 5
.  The identification of fibril forms of Aβ led to the initial hypothesis that it was 
these large precipitates of Aβ that were the pathological cause of AD.  However, recent evidence 
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shows that the much smaller, diffusible Aβ oligomers are equally or more toxic than the larger fibrils 




Tau exists in 6 isoforms with highly conserved microtubule-binding domains, through which it can 
stabilize and promote microtubule polymerization in neurons, predominantly in axons
10
. Tau is 
normally phosphorylated and soluble but in tauopathies, tau-related pathogenesis including that in 
AD, it becomes hyperphosphorylated and can accumulate into paired helical filaments, the major 
component of NFTs
10, 11
.  In AD, about 45 phosphorylation sites of tau have been determined, which 
makes the corresponding protein kinases the possible therapeutic targets
10
.  
Interestingly, recent studies have linked the tauopathy to Aβ toxicity. De Felice and colleagues found 
that tau hyperphosphorylation can be induced by Aβ oligomers
12
. A few protein kinases that can 
phosphorylate tau can be also activated in Aβ induced signaling
13, 14
. Other studies show that Aβ 
induced neurotoxicity can be tau-dependent
15, 16
. 
Current lines of investigation into the therapeutic treatment of AD are focused on finding ways to 
prevent and reverse the brain damage caused by Aβ and tau. One of the approaches is to use 
neuroprotective agents, such as neurotrophic factors, to prevent further neuronal loss and promote 
neurite growth in the early stages of AD.  
1.2. PDGF neuroprotection 
PDGF (platelet-derived growth factor) is a neurotrophic factor that has been demonstrated to be 




 and insults from HIV-1 
proteins, the putative cause of HIV-associated dementia
21-23
.   
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The PDGF ligands are hetero- or homo-dimers of PDGF-A, B, C or D chains
24
. PDGF ligands bind to 
PDGF receptors, either α- or βreceptor isoforms, with different affinities
25-27
. PDGF-A chain and 
PDGF-B chain, as well as PDGF receptors are widely expressed in both developing and mature 
central nervous system (CNS)
28
. PDGF-BB is the major species that has been implicated in 
neuroprotective effects.  
One of the possible mechanisms of PDGF neuroprotection is through inhibition on N-methyl-D-





. In one of our studies, we identified Abelson tyrosine kinase (Abl or c-Abl to 
differentiate with Arg, Abl related gene, which belongs to the same family of Abl) as a downstream 
effector of PDGF that inhibits NMDA currents by modifying the actin cytoskeleton
32
.  
1.3. NMDA receptor and AD 
NMDA receptor plays an essential role in synaptic plasticity and memory
34
 as well as excitotoxicity
35
. 
NMDA receptors are ion channels that are both ligand-gated and voltage-dependent: depolarization of 
membrane relieves the basal channel blockade by Mg
2+
 and when its natural ligand, glutamate, and 









through NMDA receptor into postsynaptic neurons triggers multiple biochemical cascades that lead to 
long term potentiation (LTP), a mechanism that underlies learning and memory
37
. However, overload 
of intracellular Ca
2+




The NMDA receptor is a tetramer containing two NR1 and two NR2 subunits, and NR2 can be 
NR2A, 2B, 2C or 2D subtype
34
. NR2A-containing NMDA receptors are mainly expressed at synaptic 
sites while NR2B-containing NMDA receptor can be found both synaptically and extrasynaptically
38
. 
Signaling through NR2A-containing NMDA receptors results in neuroprotective effects while NR2B-
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Recently, accumulating evidence shows NMDA receptors play important roles in AD pathology. 
NMDA receptors, especially NR2B-containing NMDA receptors, are required for Aβ oligomer 
induced neurotoxicity and synaptic dysfunction
40-42
. These findings are well correlated with the 
clinical effects of memantine, a non-competitive NMDA receptor antagonist approved by FDA in 
2003 in treating moderate to severe AD
43
. 
1.4. c-Abl and AD 
c-Abl is a non-receptor tyrosine kinase that is well known in oncogenesis as part of Bcr-Abl fusion 
protein resulted from Philadelphia chromosomal translocation (9:22) in chronic myeloid leukemia 
(CML), where the strictly regulated tyrosine kinase in its normal form becomes constitutively 
activated within the fusion protein
44
. STI571, also known as imatinib or Gleevec
®
, is a small molecule 
inhibitor of c-Abl that has been successfully applied in the treatment of CML
45
.  
c-Abl can be found at several subcellular locations including plasma membrane, cytoskeleton and 
nucleus
46
. It has been implicated in various biological functions from promoting cell growth to 
mediating cell death
47
. Several membrane receptors, including PDGF receptors, signal through c-
Abl
48
.  Plattner and colleagues have shown that PDGF receptor can activate c-Abl in a Src and PLCγ-
1 dependent manner
49-51
. c-Abl has actin-binding domains that can directly interact with F-actin and 
G-actin in the cytoskeleton
47
. It can also interact with several protein families to regulate actin 
dynamic indirectly. One such family is Rho family of small GTPases. Jones and colleagues found that 
Abl promote dendrite outgrowth through a RhoA/ROCK dependent manner
52
. c-Abl is expressed in 
both presynaptic and postsynaptic neurons and is concentrated in synapse-rich region, which 





. On the other hand, c-Abl is also implicated in inducing apoptosis responding to DNA 
damage and oxidative stress
53
. Numerous studies suggest c-Abl interacts with p73, a member of the 
p53 family of tumor-suppressor proteins, to induce apoptosis in response to DNA damage in 
nucleus
54-57
. In the cytoplasm, c-Abl is activated by oxidative stress and was implicated in mediating 
H2O2 induced apoptosis
58
, where its F-actin binding domain (FABD) is required
59
. 
A few studies have shown possible roles of Abl (both c-Abl and Arg) in AD pathology. One such role 
is that c-Abl can be a mediator of Aβ induced apoptosis. Alvarez and colleagues found that Aβ fibril 
can activate c-Abl and can mediate Aβ induced apoptosis
60
. Another role of Abl in AD pathology was 
attributed to its ability to phosphorylate tau. Abl can phosphorylate tau at Tyr197 (by Arg)
61
 and 
Tyr394 (by Arg and c-Abl)
61, 62
, which are among the phosphorylated sites found in the 
hyperphosphorylated tau in NFTs
10
. In both categories, STI 571, the inhibitor of Abl, was shown to be 
able to reverse the pathological effects mediated by Abl both in vitro and in vivo
63, 64
. 
1.5. Hypothesis, methodology and project outline 
Based on previous studies and the knowledge gained from investigations into the roles of NMDA 
receptors and c-Abl in AD pathology, we hypothesized that PDGF might be able to protect neurons 
against Aβ oligomer induced neurotoxicity through inhibition on NR2B-containing NMDA receptors, 
and that c-Abl may mediate this neuroprotection.  
The MTT assay is a well-accepted colorimetric method in measuring Aβ toxicity in various cell lines 
and primary neuronal cultures. The assay is based on the ability of cells to reduce MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) into purple formazan crystals, and the amount 
of formazan production correlates with the viability of cells
65
. The assay is relatively fast and easy to 
perform compared to other methods in Aβ toxicity studies and therefore was chosen to investigate 
PDGF neuroprotection against Aβ oligomer toxicity in both SH-SY5Y cells and primary neurons, as 
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well as the involvement of NR2B-containing NMDA receptor and c-Abl with pharmacological 
methods. 
Western blotting is a well-established analytical technique to quantify protein levels in a given sample 
of tissue homogenate or extract
66
. Proteins are separated in gel electrophoresis and transferred onto a 
membrane that can be probed using antibodies that specifically recognize the protein of interest. 
Advances in antibody development used in Western blotting have allowed researchers to be able to 
not only evaluate the level of certain protein in total but also quantify the phosphorylation of the 
protein at specific phosphorylation sites.  
The project was organized into three parts: 
1. Optimization of Aβ oligomer preparation and MTT assay in SH-SY5Y cells. 
The role of Aβ oligomers in AD pathology was only recognized recently. Aβ oligomers act quite 
differently from Aβ fibrils and monomers, thus it is very important to make sure the preparation of 
the oligomers is done properly and consistently. Aβ is a protein that will aggregate very easily, if the 
conditions are not well-controlled, fibrillar Aβ may ultimately become the dominant form. In 
literature, overnight incubation of Aβ in cell medium at low temperature, such as 4°C, has been 
proven to be able to produce stable, reproducible oligomers
67
. However, the details of preparation 
vary among studies depending on the cells employed. Therefore, an optimizing step was taken, 
specifically for our cell line, to ensure the prepared oligomers can exert a significant and reproducible 
toxic effect.   
The MTT assay has been established as a valuable tool to measure cell viability and proliferation for 
many years while it constantly evolves ever since. In literature, one can easily find multiple modified 
protocols being applied even for very similar research. This made it very hard to decide which one to 
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follow. Therefore, steps were taken at the beginning of the project to optimize the procedures 
involved in MTT assay in order to achieve reproducible and reliable results for the study.   
2. PDGF neuroprotection against Aβ oligomer toxicity in SH-SY5Y cells and primary neurons, 
including the examination of the roles of NR2B-containing NMDA receptor and c-Abl. 
Once the best protocols for Aβ oligomer preparation and MTT assay were determined, Aβ toxicity 
and PDGF neuroprotective effect were examined in SH-SY5Y cells and confirmed in primary 
neurons. Various dose-response experiments with specific time variations were performed. To test the 
role of NR2B-containing NMDA receptor and c-Abl in this proposed pathway, an antagonist of the 
specific NMDA receptor subtype and an inhibitor of c-Abl were used.   
3. Further mechanism exploration using Western blotting. 
At the end of the project, possible mechanisms of the observed effect of Aβ and PDGF in SH-SY5Y 
cells were further explored using Western blotting. SH-SY5Y cells were treated with the same 
dosages of Aβ1-42 oligomer and PDGF-BB as those used in MTT assay and lysed for Western blotting 
analysis. Interesting results were obtained from the analysis that explained the unexpected results in 
the cell viability assays and may provide the foundation of a novel hypothesis on Aβ induced 
neurotoxicity in AD. 
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Chapter II  
Results and Discussions 
 
2.1. Optimization of Aβ oligomer preparation and MTT assay 
The usages of Aβ and MTT assay were new to the laboratory. Therefore, a significant amount of time 
was spent on optimizing both the assay and the preparation of Aβ1-42 oligomer at the beginning of this 
project. 
2.1.1. Working with Aβ1-42: choosing the right product and establishing the aliquoting protocols 
One of the major challenges was how to properly work with the commercially available Aβ1-42. This 
includes the selection of proper Aβ1-42 products as well as the establishment of aliquoting protocols 
that involves choices of chemicals and equipment, considerations on the amount to be aliquoted and 
the storage methods. 
The Aβ1-42 used in this project was supplied by rPeptide (Georgia, USA). The DNA sequence encodes 
the human beta-amyloid (1-42) sequence and is expressed in E.coli. The supplier provides two kinds 
of Aβ1-42. One kind is associated with counter ions, which are obtained in the protein purification 
process to protonate the basic amino acid residues and N-termini. Several Aβ1-42 products with 
counter ions from NaOH, TFA (trifluoroacetate, CF3COO
-
), or HCl are available. Another kind of Aβ 
product is HFIP (hexafluoroisopropanol)-treated. HFIP is an organic solvent that is capable of 
solubilizing peptides and eliminating any pre-existing secondary structure, such as β-sheets
67
. Since 
my project was focused on Aβ oligomers, but not other forms of Aβ aggregates, such as profibril or 
fibril, I needed to eliminate any pre-existing structures from the starting material to ensure there was 
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no other forms of aggregates that might develop during the preparation process. Therefore, HFIP-
treated Aβ1-42 was chosen. 
The aliquoting step was taken for several reasons: 1) the commercially available Aβ1-42 is quite 
expensive; 2) the nature of the experiments doesn’t require a large amount of Aβ1-42 for each trial; 3) 
Aβ1-42 in solution is not stable and Aβ1-42 oligomer has to be prepared fresh, 24hr before use.  
The appropriate chemicals and equipment were purchased and prepared based on Stine’s protocol
67
 
with some modifications. Since HFIP-treated Aβ1-42 had been chosen, the solvent that was used to re-
suspend the lyophilized peptide in the first aliquoting step was HFIP. Since moisture can cause 
peptide degradation
68
, the last step was performed in a vacuum desiccator and Aβ1-42 aliquots were 
stored over desiccant in a glass desiccator at -20°C. Amber microcentrifuge tubes were used to store 
the aliquots to reduce the effects of light, another source of protein degradation. This protocol allows 
for stable peptide storage for several months to years
67
.  
The amount for each Aβ1-42 aliquot was calculated based on the final application in 96-well plates for 
MTT assay and 6-well plates for Western blotting. Although the exact amount of Aβ1-42 varied from 
experiment to experiment due to the different conditions being tested, a proper unit amount of Aβ1-42 
was determined for both MTT assay and Western blotting to eliminate any waste. Therefore, multiple 
aliquots were used for each experiment depending on the specific conditions involved. A slight 
addition (about 5%) to the desired amount was applied in the calculation since there were hundreds of 
pipetting steps involved in each experiment that could lead to a significant build-up of small pipetting 
errors. The concentration of HFIP solution in the re-suspension step was adjusted to a lower 




Each Aβ1-42 aliquot was labeled with a number in the order of the addition of the HFIP-dissolved Aβ1-
42 stock from each vial. The reason for doing this was based on the practice of always getting fewer 
aliquots than expected. For example, according to calculation, I was supposed to get 17.7 aliquots 
from 1 mg of Aβ1-42 with 56.46 μg in each aliquot. However, in reality there might just be 16.2 
aliquots. This phenomenon was due to the nature of HFIP being highly volatile. During the process of 
aliquoting under the fume hood, HFIP kept evaporating when each aliquot was prepared with the 
addition of the same volume of the solution. As a result, the aliquots being prepared at the end 
contained more Aβ1-42 than the aliquot being prepared at the beginning. This problem could not be 
avoided even the process was done quickly. The different amount between the first aliquot and the 
last aliquot led to about 10% difference on the concentrations of the Aβ1-42 oligomer stock solution 
(100 μM) prepared on day 2 (see Table 1). The labeled number was used to track the order of the 
preparation so a combination of aliquots that were prepared earlier and later could be used to help 
maintain consistency among experiments.  
2.1.2. MTT assay: the four-day routine 
The major portion of the project was to test PDGF-BB neuroprotection against Aβ1-42 oligomer 
induced toxicity using MTT assay. Every trial followed the same four-day routine (Table 1) to 
generate results and all the key aspects in this routine were carefully considered and/or optimized. 
Table 1: Four-day routine of MTT assay in the study of PDGF-BB neuroprotection against Aβ1-42 
oligomer induced toxicity. 
Day 1 Plating cells 
Day 2 Serum starvation and Aβ1-42 oligomer preparation 
Day3 Treatment 
Day4 MTT assay - adding MTT, MTT formazan solubilization and absorbance measurement 
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Day 1: Determination of the best cell densities 
A good resolution for MTT assays depends on identifying an ideal working cell density because the 
MTT assay measures the activity of metabolically viable cells. If there are too many cells, the toxic 
effect may not be detectable by the assay since only a small portion of cells will be affected.  
According to the manufacturer’s instructions, the recommended cell density for the MTT (Sigma) 











according to the known surface area of each well to be 0.32cm
2
 and volume of cell culture in each 





 difference between the recommended maximum density and those in literature. 













). As can be seen in Figure 1, the lower 
cell density provided a better resolution toward the same dosage of Aβ1-42 oligomer. Therefore the 
working cell density was determined in the 10
5
/ml range.  

























/ml, and exposed to Aβ1-42 oligomer at various concentrations. Cell viability 
was measured by MTT assay (n=1). 
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Within this determined range, several densities were tested along with other optimization steps to 




/ml provided the most 
consistent results and working with either of these two densities did not make any difference on Aβ1-
42 oligomer induced toxicity in SH-SY5Y cells. However, 1×10
5
/ml was mostly used as it always 
gave clear color differences among treatments that were readily observable.  
Since primary neuronal cells are more challenging to grow compared to SH-SY5Y cells and we had 
not previously grown primary neurons on 96-well plates, I plated primary neurons on 96-well plates 




/ml. The results showed no difference with respect to the Aβ1-
42 oligomer induced toxicity in the two cell densities in primary neurons (Figure 3 and Figure 4). 
Day 2: Serum starvation and Aβ1-42 oligomer preparation 
Prior to beginning the assay, the cells were serum-starved. The serum starvation step was conducted 
for two reasons. The first reason was to reduce cell division promoted by serum components and 
encourage the development of neuronal features, a process called differentiation. The second reason 
was to remove PDGF specifically as it is present in the serum supplement.   
Cells were serum starved about 24hr after being plated. This 24hr time period was given to allow the 
cells to establish attachment after plating. After the medium was changed to serum-free medium in 
the serum starvation step, another 24hr was given to encourage the cells to develop neuronal features.  
Another key benefit of serum starvation was to remove phenol red from the culture. Phenol red is a 
pH indicator that is commonly added to cell culture medium to monitor the pH changes that are 
crucial for cell growth. However, the presence of phenol red would contribute to a higher background 
absorbance and decrease the sensitivity of MTT assay. Therefore, I used phenol red free medium in 
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the serum starvation step instead of regular serum-free medium. This removal of phenol red from the 
medium helped eliminate the background noise and enhanced the sensitivity of the measurement. 
Aβ1-42 oligomer preparation was performed on day 2 as well because there was a 24hr-incubation at 
4°C required for oligomer formation immediately before the treatment. 
In the literature, two Aβ1-42 oligomer preparation protocols were commonly used. One was 
determined by Stine and colleagues
67
 and another was developed by Lambert and colleagues
6
. Both 
protocols produced high quality oligomers evaluated by atomic force microscopy (AFM) and Western 
blotting
6, 67
. The major similarities and differences between the two protocols in the order of the 
procedures are summarized in Table 2. 
Table 2: Similarities and differences between Stine’s and Lambert’s protocols. 
 
As can be seen in Figure 2, Stine’s protocol gave a better correlation between the cell viability signal 
and the known cell density compared to Lambert’s protocol. The usage of DMSO in dissolving the 
HFIP treated Aβ1-42 film as the first step in Stine’s protocol may play an essential role in the better 
result. This step was suggested to be indispensable to ensure fully solubilization of the HFIP treated 
peptide and proven to be able to produce uniform and unaggregrated oligomer structures which could 
not be generated by directly dissolving in water
67
. Additionally, the centrifugation step did not seem 
to be necessary for the small amount of Aβ1-42 in each aliquot in this project since there was no visible 
pellet formed after the step. Therefore Stine’s protocol was chosen for the following viability assays.  
 Stine’s Lambert’s 
Dissolved in DMSO (5mM) with sonication (10min) Yes No 
Diluted in cold medium (100μM) with vortex Yes Yes 
Incubated at 4°C, 24hr Yes Yes 
Centrifuged before treatment No Yes 
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Figure 2: Determination of Aβ1-42 oligomer preparation protocols. SH-SY5Y cells in different cell densities 
were exposed to 10 μM Aβ1-42 oligomer for 24hr. Two Aβ1-42 oligomer preparation protocols, Stine’s protocol 
and Lambert’s protocol, were examined. Cell viability was measured by MTT assay (n=3-4). 
Day 3: Treatment 
Cell treatment was performed after Aβ1-42 oligomer preparation was completed. Reagents were added 
sequentially without mixing even for the co-treatment to eliminate any possible interactions between 
the reagents prior to the exposures to the cells. For Aβ1-42 oligomer, once the incubation time was 
completed, the aliquots were combined as one pool to eliminate errors caused by any discrepancy that 
may exist between the aliquots. Since MTT assay directly measures absorbance, which is proportional 
to the concentration according to Beer-Lambert Law, the volume in each well was maintained the 
same for all treatments. Therefore, each well was treated with the same volume in each treatment, and 
for the control wells where the reagent was absent, the solvent of that reagent was added to ensure the 
same volume per well. For Aβ1-42 treatment, the additional amount of solvent was prepared and 




Day 4: Optimization of MTT formazan solubilization 
After 3hr of incubation with MTT, MTT formazan appeared as needle-like purple crystals around the 
cells. These crystals have to be dissolved into solution in a solubilization step before the absorbance is 
measured. This solubilization step is very important because it will cause errors in the absorbance 
reading if the crystals are not completely dissolved. While many solubilization buffer recipes exist, I 
chose the one used in Sigma’s TOX1 MTT kit to match well with the MTT that was also purchased 
from Sigma. Beside the solubilization recipes, the solubilization methods were also quite different 
among different study groups. One might take off the medium before adding solubilization buffer 
while the other would leave the medium in and incubate with the solubilization buffer overnight. To 
determine the best method, I tried several options (Table 3) and generated a standard curve against 
cell densities for each of them (data not shown). Based on the standard curves, Option 1 was chosen 
because it showed a better sensitivity at the desired cell density range and was relatively less labor 
and time intensive. 
Table 3: Optimization of MTT formazan solubilization. 
Option 1 Medium-in, 3hr incubation 
Option 2 Medium-in, overnight incubation 
Option 3 Medium-off , 3hr incubation 
Option 4 Medium-off , overnight incubation 
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2.2. PDGF neuroprotection against Aβ oligomer toxicity 
 
2.2.1. Aβ1-42 oligomer toxicity 
Aβ toxicity has been studied in many ways in different cell types. Although SH-SY5Y cells are one 
of the common cell lines used in these studies, there was no clearly demonstrated dose-response curve 
for Aβ toxicity in SH-SY5Y cells previously in literature. In this project, SH-SY5Y cells were 
exposed to 10 nM to 10 μM Aβ1-42 oligomer for 24hr and a dose response curve was generated 
(Figure 3). The resulting curve showed a concentration-dependent decrease in cell viability in 
response to Aβ1-42 oligomer treatment in SH-SY5Y cells.  



















Figure 3: Aβ1-42 oligomer induced toxicity in SH-SY5Y cells. SH-SY5Y cells (0.5-1×10
5
/ml) were exposed to 
different concentrations of Aβ1-42 oligomer from 10 nM-10 μM for 24hr and the cell viability was measured by 
MTT assay (n=4). 
A series of dose-response curves was also obtained from primary hippocampal neurons. These dose-
response curves were in a similar shape as observed for SH-SY5Y cells. However, the primary 
neurons seemed to be more susceptible to the same amount of Aβ1-42 oligomer than SH-SY5Y cells. 
This is common for other toxicity effects as well and probably due to the nature of primary cells 
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being more vulnerable under culturing condition
69
, or possibly because they are “true neurons” that 
lack the ability to divide. Another characteristic of these curves is that the curves for DIV (days in 
vitro) 5 neurons and DIV10 neurons are largely similar. This indicates that the development of 
neuronal network within 10 days does not have significant impact on the toxic effect. 
The dose-response curve obtained here will provide valuable information for similar studies on other 
neuroprotective agents against Aβ1-42 oligomer in SH-SY5Y cells and primary neurons in the future. 























Figure 4: Aβ1-42 oligomer induced toxicity in primary hippocampal neurons. Embryonic mouse 
hippocampal neurons (0.5 and 1×10
5
/ml) were exposed to different concentrations of Aβ1-42 oligomer from 10 
nM-10 μM for 24hr and the cell viability was measured by MTT assay (n=4-5). 
In the dose-response curves for both SH-SY5Y cells and primary neurons, there was an interesting 
feature: a sign of saturation of Aβ1-42 oligomer induced toxicity. The relative cell death was more 
sensitive at lower dosages of Aβ1-42 oligomer while at concentration higher than 1 M there was no 
significant further reduction of cell viability.  
This sign of saturation is very similar to what one would expect to see in a typical ligand-receptor 
binding curve where a saturation of binding will be reached at certain concentration of the ligand. 
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Therefore, it is possible that Aβ1-42 oligomer may bind to membrane receptors to elicit its toxicity. 
This possible binding mechanism is consistent with findings from other studies. For example, Klein’s 
group found that Aβ oligomer can bind to two membrane proteins from rat hippocampus and cortex 
with high binding affinity (~1 nM range)
70
.  
2.2.2. Other methods of measuring Aβ1-42 oligomer toxicity 
The MTT assay has been well accepted as a simple yet valuable method to measure Aβ (both fibril 
and oligomer) toxicity. However, as with other methods, it has its own limitations: it only reflects the 
ability of cells to reduce MTT and possibly the ability to transport the MTT formazan out of cell 
membrane by exocytosis
71-73
. Although the impaired metabolic activity and vesicle trafficking might 
be originated from the same trigger that causes other parallel toxic effects, it would be worthwhile to 
use other assays to confirm the MTT reduction results in the future when it comes to a more advanced 
stage of screening for neuroprotective agents against Aβ toxicity. In this way, one can look into if the 
neuroprotective agents can protect neurons against other toxic effects caused by Aβ. There are several 
other simple methods that are commonly used in measuring various aspects of Aβ toxicity (Table 4).  
Table 4: Commonly used assays in Aβ toxicity studies. 
Assays Measuring or Identifying Indicating 
LDH assay Lactate dehydrogenase release Damaged membrane 
ATP assay Cellular ATP level ATP depletion 
TUNEL assay DNA fragmentation Apoptosis 
The LDH assay is used to measure membrane integrity
74
. Lactate dehydrogenase (LDH) is released 
when cell membrane is damaged. The assay measures LDH activity by introducing a coupled 
colorimetric reaction. The increase of LDH activity correlates to the increase of lysed cells. 
Compared to the MTT assay that measures the changes in metabolic activities happening in the early 
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stage of Aβ induced cell-death, LDH assay measures the later stage of the process that involves cell 
membrane rupture.  
Another method is to measure cellular ATP levels using a bioluminescent method where an enzyme, 
luciferase, is used to catalyze the formation of light from ATP and luciferin and the light intensity is 
linear to ATP concentration
75
.  ATP depletion has been considered as a sign of Aβ induced neuronal 
degeneration that involves mitochondrial dysfunction that leads to synaptic loss and neuronal death
76-
78
.   
TUNEL (TdT-mediated dUTP Nick End Labeling) assay is a qualitative method to detect DNA 
fragmentation, a key indication of apoptosis
79
. TdT stands for terminal deoxynucleotidyl transferase, 
an enzyme that catalyzes the addition of fluorochrome-tagged dUTPs to the nicks that contains free 
3′-OH termini in fragmented DNA. This method has been widely used in studies where apoptosis 
might be involved, including Aβ toxicity
80, 81
 and PDGF neuroprotection
17, 23
.  
Besides these simple methods, one can also monitor the change of neuron-specific protein, MAP2 
(microtubule-associated protein 2) in primary neurons in Aβ toxicity studies. We have previously 
used this method in studying PDGF neuroprotection against NMDA induced toxicity in primary 
neurons
33




2.2.3. PDGF-BB neuroprotection against Aβ1-42 oligomer toxicity and the involvement of NR2B 
containing NMDA receptors 
PDGF-BB neuroprotection against Aβ1-42 oligomer was examined in several experimental protocols 
where both PDGF-BB and Aβ1-42 concentrations were varied and PDGF-BB was also given additional 
30min before Aβ1-42 treatment in SH-SY5Y cells. Table 5 is a summary on how the experiments were 
presented in the corresponding figures for SH-SY5Y cells. 
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response,  Aβ1-42=5 μM 
Co-treatment Figure 5 Figure 7 
PDGF-BB 30min pretreatment before Aβ1-42 exposure Figure 6 Figure 8 
Although PDGF-BB has been implicated to be neuroprotective against many neurodegenerative 
agents, PDGF-BB failed to provide a strong protection against Aβ1-42 oligomer induced toxicity in 
both SH-SY5Y cells (Figures 5-8) and primary neurons (Figures 9-10): at all the tested concentrations 
for both Aβ1-42 and PDGF-BB, PDGF-BB elicited a slight to no neuroprotective effects, even when 
PDGF-BB was applied 30min prior to induce the neuroprotective cascades before the exposure to 
Aβ1-42 oligomer (Figures 6 & 8). Clearly, PDGF-BB-induced neuroprotective effects were not 
sufficient enough to protect neurons against Aβ1-42 oligomer induced toxicity.  
A simple question arose at this point: was PDGF-BB given enough time to elicit its protective effect 
against Aβ1-42 oligomer? Previous evidence shows that PDGF-BB is able to inhibit NMDA-evoked 
current in a manner that depends on NR2B containing NMDA receptors and reduce the surface 
expression of this NMDA receptor subtype within 10min, possibly through internalization of the 
receptors
33
. Since the mechanism of PDGF neuroprotection against Aβ oligomer toxicity was 
hypothesized to be through inhibition on NR2B containing NMDA receptors, 30min pre-treatment 
should have been able to prevent the damage caused by Aβ1-42 through these receptors. However, this 
was not the case. One explanation could be the NMDA receptors are not involved in the proposed 
pathway. Further experiments on the involvement of NR2B containing NMDA receptor corroborated 
this explanation. As seen in Figure 11, application of Ro25-6981, a selective antagonist of NR2B 
containing NMDA receptors, did not alter Aβ1-42 oligomer induced toxicity any further and the slight 




































































Figure 5: Neuroprotective effect of PDGF-BB at 10 ng/ml against toxicity of Aβ1-42 oligomer at various 
concentrations (co-treatment) in SH-SY5Y cells. (A) (B) SH-SY5Y cells (0.5-1×10
5
/ml) were exposed to 
Aβ1-42 oligomer at various concentrations in the presence or absence of PDGF-BB at 10 ng/ml for 24hr. Cell 




































































Figure 6: Neuroprotective effect of PDGF-BB at 10 ng/ml against toxicity of Aβ1-42 oligomer at various 
concentrations (PDGF-BB 30min pretreatment) in SH-SY5Y cells. (A) (B) SH-SY5Y cells (1×10
5
/ml) were 
exposed to Aβ1-42 oligomer at various concentrations for 24hr in the presence or absence of PDGF-BB at 10 






























































Figure 7: Neuroprotective effect of PDGF-BB at various concentrations against toxicity of Aβ1-42 oligomer 
at 5 μM (co-treatment) in SH-SY5Y cells. (A) (B) SH-SY5Y cells (1×10
5
/ml) were exposed to Aβ1-42 
oligomer at 5 μM in the presence or absence of PDGF-BB at various concentrations for 24hr. Cell viability was 































































Figure 8: Neuroprotective effect of PDGF-BB at various concentrations against toxicity of Aβ1-42 oligomer 
at 5 μM (PDGF-BB 30min pretreatment) in SH-SY5Y cells. (A) (B) SH-SY5Y cells (1×10
5
/ml) were 
exposed to Aβ1-42 oligomer at 5 μM for 24hr in the presence or absence of PDGF-BB at various concentrations 






































































































































Figure 9: Neuroprotective effect of PDGF-BB at 10ng/ml against toxicity of Aβ1-42 oligomer at various 
concentrations (co-treatment) in primary neurons (DIV5). Embryonic mouse hippocampal neurons (DIV5) 
were exposed to Aβ1-42 oligomer at various concentrations in the presence or absence of PDGF-BB at 10 
ng/ml for 24hr. Cell viability was measured by MTT assay. (A) (B) cell density = 0.5×10
5
/ml (n=5); (C) (D) 






































































































































Figure 10: Neuroprotective effect of PDGF-BB at 10 ng/ml against toxicity of Aβ1-42 oligomer at various 
concentrations (co-treatment) in primary neurons (DIV10). Embryonic mouse hippocampal neurons 
(DIV10) were exposed to Aβ1-42 oligomer at various concentrations in the presence or absence of PDGF-BB at 
10 ng/ml for 24hr. Cell viability was measured by MTT assay. (A) (B) cell density = 0.5×10
5
/ml (n=5); (C) (D) 
























































Figure 11: The involvement of NR2B containing NMDA receptor in PDGF-BB neuroprotective effect 
against Aβ1-42 oligomer. (A) (B) SH-SY5Y cells (1×10
5
/ml) were exposed to NR2B containing NMDA 
receptor antagonist Ro25-6981 at various concentrations immediately before the exposure to Aβ1-42 oligomer at 





However, it might be too early to conclude that NMDA receptors are not involved in Aβ induced 
toxicity. A recent study (2011) shows Aβ1-42 oligomer induced apoptotic cell death is dependent on 
ionotropic glutamate receptors including NMDA receptors: 24hr treatment of Aβ1-42 oligomer in 
cultured cortical neurons induced dose-dependent cell death measured by LDH assay and this effect 
was attenuated by NMDA antagonists AP5, MK801 and memantine
83
. These results may be due to 
the many differences in the materials and methods being used, such as cell type, cell death assay and 
NMDA receptor antagonist.  
SH-SY5Y cells have been used in numerous studies on NMDA receptors
84-87
 and we have 
preliminary data from our laboratory showing the expression of NMDA receptors, including NR2B 
subunit, in this cell line. However, evidence for the functionality of the receptors in SH-SY5Y cells is 
contradictory. Some studies have shown the receptors can be activated by their agonists, such as 
NMDA and glutamate
88
 and the NMDA receptor antagonist, MK801, is able to block the studied 
effect
87
; while others didn’t see the receptor as functional
89, 90
. One explanation of the discrepancy 
could be the possibility of phenotype changes during passages in the tumor-originated cells. 
Therefore, it would be worthwhile to repeat the experiment in primary neurons in the future. 
The MTT assay has been widely used in many similar neuroprotective studies against Aβ toxicity
78, 81, 
91-93
. However, as indicated in the Aβ toxicity section in this report, MTT assay does have limitations 













 and neuronal 
morphological changes
97, 98
. The references on each of these Aβ toxic effects provide the 
corresponding quantitative and/or qualitative methods that should be considered among the 
limitations of using MTT assay alone in future studies.  
The NR2B containing NMDA receptor has been implicated to be the major player of inducing 
excitotoxicity after neuronal insults
39
. The same NMDA receptor subtype is also implicated in having 
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a pathological role in Alzheimer’s disease
41, 80
. However, there is also a report showing the 
contradictory roles of these NMDA receptor subtypes: Texido and colleagues reported recently that 
Aβ1-42 oligomer directly activated NMDA receptors with a  preferential activation of NR2A-
containing NMDA receptors compared to NR2B subtypes and that the antagonist of NR2B containing 
NMDA receptors, ifenprodil, only slightly attenuated Aβ1-42 oligomer induced Ca
2+
 overload 
compared to the broad spectrum NMDA receptor antagonist, AP5
99
. Therefore, at the early stages of 
this study, it might be useful to start with NMDA receptor antagonists that are not specific for any 
subtypes, such as MK801, AP5 and memantine, prior to using subtype-selective antagonists.  
Furthermore, it might be also too early to exclude PDGF neuroprotective effects against Aβ 
oligomers without testing Aβ oligomer induced synaptic dysfunction, another significant aspect of Aβ 
oligomer toxicity. Mounting evidence suggests that cognitive impairment in Alzheimer’s disease 
starts with subtle alterations of synaptic function before neuronal loss becomes evident
100, 101
.  Many 
studies have suggested soluble Aβ oligomers may affect synaptic function through NMDA 
receptors
40, 102
. A recent electrophysiology study (2011) shows that Aβ1-42 oligomers can inhibit long-
term potentiation (LTP) in murine hippocampal slices and NR2B containing NMDA receptor 
antagonists, including Ro25-6981, at 300nM, can reverse this effect
103
. This finding on the effects of 
NR2B containing NMDA receptor antagonists against Aβ oligomer induced synaptic deficits is in 
line with our previous findings that PDGF-BB is inhibitory on the same NMDA receptor subtype 
using the same method and antagonist
33
.  Therefore, more thorough studies on Aβ oligomer induced 
synaptic dysfunction, especially the effect on LTP, will help clarify the protective role of PDGF-BB 
against Aβ oligomer toxicity from a new angle.  
2.2.4. The involvement of c-Abl 
Another axis of this study was to test the role of c-Abl. c-Abl is a downstream effector of PDGF β-
receptor mediated signaling pathway
51





. c-Abl is also implicated as a mediator in Aβ induced apoptosis
63, 64
. To determine the role 
of c-Abl in the proposed pathway, bosutinib, a c-Abl inhibitor was applied in the presence and 
absence of Aβ1-42 oligomer and PDGF-BB. Figure 12 showed at all the tested dosages of bosutinib, 
neither the Aβ1-42 oligomer induced toxicity nor the slight to no neuroprotective effect of PDGF-BB 
was altered.  


















































Figure 12: The involvement of c-Abl in PDGF-BB neuroprotective effect against Aβ1-42 oligomer. (A) (B) 
SH-SY5Y cells (1×10
5
/ml) were exposed to c-Abl inhibitor bosutinib at various concentrations for 30min 
before the exposure to Aβ1-42 oligomer at 5 μM and/or PDGF-BB at 10 ng/ml for 24hr. Cell viability was 
measured by MTT assay (n=8). 
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The unchanged Aβ oligomer induced toxicity by the addition of bosutinib is contradictory to the 
findings using another c-Abl inhibitor, STI571 (or imatinib) in the study of Aβ fibrils induced cell 
death
60, 64
. This might simply due to the two inhibitors used have slightly different targets. STI571, 
although has been widely used to inhibit c-Abl activity, has also been found to inhibit other tyrosine 
kinases such as PDGF receptors
104
; while bosutinib is a Src/Abl dual inhibitor
105
 that lacks activity 
against PDGF receptors
104
. Another more plausible explanation is Aβ oligomer may elicit its toxicity 
through a different pathway that is not dependent on c-Abl as in Aβ fibril induced cell death.  
Aβ fibrils and oligomers are quite different in shape and size. Since Aβ oligomer (or ADDL, amyloid-
beta-derived diffusible ligand) induced toxicity became evident in recent studies, the preparations of 
the two species was defined in details and were often confirmed by AFM and/or Western blotting for 
their distinct sizes and shapes. Aβ fibrils are fiber-like protein aggregates (~4 nm in z-height and >1 
μm in length)
106
 with molecular weight in 50-100KDa
106
. They are mainly recognized as non-
diffusible extracellular deposits
6
. In contrast, Aβ oligomers appear as globular structures (~2-6nm in 
z-height)
106,6
 with the predominant species in the 17-42KDa
6
 range comprising monomers, trimers, 
and tetramers
106
. These Aβ oligomers are soluble, membrane diffusible and have ligand-like features
6
.  
Although it is true that both species induce neurotoxicity, the magnitude and cellular response are 
quite different. Dahlgren and colleagues reported Aβ oligomer is 10-fold stronger than Aβ fibril in the 
inhibition of neuronal viability measured by MTT assay
106
. White and colleagues showed Aβ 
oligomer can induce inflammatory response more rapidly and potently than Aβ fibril
107
. Lee and 
colleagues found Aβ oligomer is more toxic than fibril in a negative effect on Akt activation
108
. 
Sondag and colleagues found Aβ1-42 oligomer and fibril stimulate different signaling responses in 
microglia that lead to discrete effects on neuronal survival
109
. These findings imply that the two 
species may take different routes to neurotoxicity. 
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c-Abl is a non-receptor tyrosine kinase whose activity is strictly regulated: the kinase stays in an 
inactive form and becomes activated only in response to various stimuli. This strict regulation might 
be due to the fact that c-Abl can conduct distinct and even opposite signals, such as mediating both 
cell survival and cell death, depending on the nature of the stimuli. For example, c-Abl can response 
to growth factor stimuli and promote cell proliferation
50, 51
; while on the other hand, c-Abl can 
mediate apoptosis in response to DNA damage and oxidative stress
53
. In this investigation, the role of 
c-Abl in affecting cell viability is absent: there was no sign of suppressing or promoting cell viability 
(Figure 12). This could be due to the limitations of MTT assay that is only reflecting the change of 
metabolic activities in cells, which is not necessarily in close linkages to the activity of c-Abl in either 
cell growth or cell death pathways. Sims and colleagues found imatinib (STI571), another c-Abl 
inhibitor, can interfere with MTT assay and cause false results
110
.  Therefore, other complementary 
cell viability assays should be used in future studies to corroborate the results. 
2.2.5. A novel hypothesis 
Besides the limitations of the experimental methods that may contribute to the lack of our expected 
results, an interesting observation throughout all the trials of the neuroprotection experiments may 
provide another explanation. As can be seen in Figure 5-12, in contrast to the poor protection elicited 
by PDGF-BB, Aβ1-42 oligomer potently inhibited the neurotrophic effect induced by PDGF-BB. This 
observation not only provided a vital explanation on the slight to no neuroprotective effect induced by 
PDGF-BB, but also led to a novel hypothesis: Aβ oligomers may provoke neurotoxicity, at least 
partially, by inhibiting neurotrophic pathways. In order to test this hypothesis, a phosphorylation site, 
tyrosine 1021 (Tyr1021), on PDGF β-receptor was chosen to see if Aβ1-42 oligomer can alter ligand-
induced PDGF receptor phosphorylation. The results of this experiment were positive and may 
explain why PDGF-BB failed to protect neurons from Aβ1-42 oligomer.   
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2.3. Aβ oligomer effects on PDGF receptor signaling 
 
2.3.1. Phosphorylation of PDGF β-receptor at Tyr1021 
PDGF-BB triggers neuroprotective pathways through binding to PDGF β-receptors
20, 27, 29
. The ligand 
binding results in receptor dimerization and activation of the receptor’s intrinsic kinase activity. As a 
result, receptor trans-phosphorylation occurs at multiple tyrosine residues which in turn become 
binding sites to recruit molecules that will transduce signals further. The residue Tyr1021 near the C-
terminal of the receptor is one of the sites activated during trans-phosphorylation upon ligand binding 
and was chosen as the first site to investigate the influence of Aβ oligomer on PDGF β receptor 
activation.  
The investigation began by repeating the same conditions as in the MTT assay: SH-SY5Y cells were 
treated with Aβ1-42 oligomer at 5 μM and PDGF-BB at 10 ng/ml together for 24hr. The result shows 
that Aβ1-42 oligomer exhibited a potent inhibition on PDGF-BB induced PDGF β-receptor 
phosphorylation at Tyr1021: the co-treatment decreased the phosphorylation by about 1/3 (Figure 13).  
In order to clarify this inhibition by Aβ1-42 oligomer, the initial effect of PDGF-BB on the receptor 
phosphorylation was excluded by incubating the cells with Aβ1-42 oligomer alone for 24hr first 
followed by stimulating the phosphorylation by PDGF-BB for just 10min before the cells were lysed. 
As expected, the inhibitory effect became more apparent: 24hr treatment by Aβ1-42 oligomer at 5 μM 
reduced PDGF-BB induced PDGF β-receptor phosphorylation at Tyr1021 by more than 2/3 (Figure 
14). 
Then the investigation was pushed even further by asking if a simple, acute treatment of Aβ1-42 
oligomer can cause the same inhibitory effect. Cells were treated with Aβ1-42 oligomer for only 10min 
before being stimulated by PDGF-BB. Interestingly, this acute treatment of Aβ1-42 treatment at the 
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same concentration (5 μM) was enough to block the PDGF-BB induced PDGF β-receptor 
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Figure 13: Aβ1-42 oligomer treatment for 24hr suppressed PDGF-BB induced PDGF β-receptor 
phosphorylation at Tyr1021 (Aβ1-42 and PDGF-BB co-treatment). SH-SY5Y cells were exposed to Aβ1-42 
oligomer at 5 μM for 24hr in the presence or absence of PDGF-BB at 10 ng/ml. Western blot membranes were 
probed with phospho-PDGF -receptor (Tyr1021) antibody, stripped, and re-probed with PDGF -receptor 
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Figure 14: Aβ1-42 oligomer treatment for 24hr suppressed PDGF-BB induced PDGF β-receptor 
phosphorylation at Tyr1021 (PDGF-BB 10min stimulation). SH-SY5Y cells were exposed to Aβ1-42 
oligomer at 5 μM for 24hr before stimulated by PDGF-BB at 10 ng/ml for 10min. Western blot membranes 
were probed with phospho-PDGF -receptor (Tyr1021) antibody, stripped, and re-probed with PDGF -
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Figure 15: Aβ1-42 oligomer acute treatment for 10min suppressed PDGF-BB induced PDGF β-receptor 
phosphorylation at Tyr1021 (PDGF-BB 10min stimulation). SH-SY5Y cells were exposed to Aβ1-42 
oligomer at 5 μM for 10min before stimulated by PDGF-BB at 10 ng/ml for 10min. Western blot membranes 
were probed with phospho-PDGF -receptor (Tyr1021) antibody, stripped, and re-probed with PDGF -
receptor antibody. Blots are representative of 3 independent experiments. * p < 0.05, t-test. 
These findings provided an explanation for the results obtained from MTT assays. Phosphorylated 
Tyr1021 is the major binding site of PLC-γ
111
, a 145-kDa protein that catalyzes the hydrolysis of a 
phospholipid, phosphatidylinositol 4,5-bisphophate (PIP2) and leads to the production of two 
secondary messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)
112
. IP3 is known to 
stimulate internal Ca
2+
 release from endoplasmic reticulum (ER) and DAG can work with the 
increased Ca
2+
 to activate protein kinase C (PKC), a serine and threonine kinase
112
 that plays a role in 
triggering cell proliferation and differentiation
113
. Phosphorylation at Tyr1021 is required for a stable 
association of the receptor with PLCγ, PDGF-dependent IP3 production, and maximal DNA synthesis, 
a mitogenic response induced by PDGF-BB
25
. Therefore, the poor neuroprotective effect of PDGF-
BB against Aβ1-42 oligomer and the potent inhibitory effect of Aβ1-42 oligomer on PDGF-BB induced 
promotion on cell survival that consistently appeared throughout all the MTT assays may be due to 
the fact that PDGF-BB’s effects were inhibited by Aβ1-42 oligomers throughout these experiments. 
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These findings also partially supported our novel hypothesis that Aβ oligomers may elicit their 
neurotoxicity through inhibition on neurotrophic pathways (Figure 16). Neurotrophic factors (NTFs) 
play important roles in both developing and mature nervous systems. Although the production is 
declined after the early development, neurotrophic factors continue to nurture adult brains by 
maintaining healthy neuronal populations for optimal survival and function
114, 115
.  Many studies have 
shown that NTF function may be disturbed in neurodegenerative diseases including Alzheimer’s 
disease: the levels of some NTFs and their associated receptors were found being altered in AD brains 
and there are strong association between some NTFs and the formation of neurofibrillary tangles and 
senile plaques
116-118
. However, less attention has been paid to the mechanism of how NTF function is 
affected. The findings in this study on the inhibitory effect of Aβ oligomer on PDGF receptor 
activation may provide some insights into the alteration of NTF function in AD. The altered levels of 
NTFs and NTF receptors might be due to the strong inhibition of Aβ oligomers on NTF receptor 
activation and the affected brains may attempt to express more NTFs and/or NTF receptors to foster 
the activation. Since NTF signaling pathways may be targeted by Aβ oligomers, it is not surprising to 
see the presence of NTFs at the sites where Aβ oligomers start to accumulate to form senile plaques 















Figure 16:  A novel hypothesis of Aβ oligomer induced toxicity in Alzheimer’s disease. Aβ oligomers may 
elicit their toxicity through inhibition on neurotrophic factor (NTF) signaling pathways that are essential for 
maintaining healthy neuronal population in the mature central nervous system. The activation of NTF receptors 
by their ligands is blocked by Aβ oligomers possibly through a way that Aβ oligomers may act as antagonists of 



















2.3.2. Other effects of Aβ1-42 oligomer on PDGF β-receptor signaling 
Some efforts were made in this project to elucidate the Aβ oligomer inhibition mechanism by 
examining the level of PDGF β-receptor, the phosphorylation and expression of extracellular-signal 
regulated kinase 1/2 (Erk1/2) in SH-SY5Y cells.  
Treatment of Aβ1-42 oligomer for 24hr didn’t change the level of PDGF β-receptor comparing to the 
control (Figure 17 &18). This finding excluded the possibility that Aβ1-42 oligomer may affect PDGF 
receptor signaling by regulating the receptor expression. Interestingly, co-treatment of Aβ1-42 
oligomer with PDGF-BB for 24hr didn’t block the down-regulation of the receptor induced by its 
ligand (Figure 17); while when the cells were pre-exposed to Aβ1-42 oligomer for 24hr before the 
PDGF-BB stimulation for 10min, there was a slight but significant reduction of the down-regulation 
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Figure 17: Aβ1-42 oligomer treatment for 24hr didn’t alter the protein level of PDGF β-receptor (Aβ1-42 
and PDGF-BB co-treatment). SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 μM for 24hr in the 
presence or absence of PDGF-BB at 10 ng/ml. Western blot membranes were probed with PDGF -receptor 
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Figure 18: Aβ1-42 oligomer treatment for 24hr slightly hindered PDGF-BB induced PDGF β-receptor 
down-regulation (PDGF-BB 10min stimulation). SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 μM 
for 24hr before stimulated by PDGF-BB at 10 ng/ml for 10min. Western blot membranes were probed with 
PDGF -receptor antibody, stripped, and re-probed with β-actin antibody as a loading control. Blots are 
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Figure 19: Aβ1-42 oligomer acute treatment didn’t affect PDGF-BB induced PDGF β-receptor 
degradation. SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 μM for 10min before stimulated 
by PDGF-BB at 10 ng/ml for 10min. Western blot membranes were probed with PDGF -receptor 
antibody, stripped, and re-probed with β-actin antibody as a loading control. Blots are representative 
of 4 independent experiments. 
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The ligand induced receptor down-regulation is mediated through receptor internalization and 
degradation, which is common among many receptor tyrosine kinases
119-121
. It was found that 
activation of PDGF receptors promotes the degradation but is not required
122
. It is possible that Aβ1-42 
oligomer only partially affected the activation of the receptors and the receptor internalization and 
degradation was induced by its ligand very quickly before being affected by Aβ1-42 oligomer. Besides, 
the slight change of the receptor degradation required long-time exposure of Aβ1-42 oligomer.  
Erk is an important downstream effector of PDGF-induced mitogenesis. Evidence has shown Erk 
may mediate the neuroprotective effect elicited by PDGF-BB against HIV1 Tat induced cytotoxicity  
in the context of HIV-associated dementia (HAD)
21
 and against H2O2 induced cytotoxicity
20
 that 
mimics the oxidative stress happened in many neurological disorders, including Alzheimer’s 
disease
123
. Therefore, it was of interest to examine if Erk could be affected by Aβ oligomer treatment.  
As can be seen in Figure 20-22, Aβ1-42 oligomer didn’t change the basal or the induced levels of Erk 
phosphorylation in all three conditions: Aβ1-42 oligomer and PDGF-BB co-treatment for 24hr (Figure 
20), Aβ1-42 oligomer pre-treatment for 24hr before PDGF-BB stimulation for 10min (Figure 21), and 
Aβ1-42 oligomer acute treatment for 10min before PDGF-BB stimulation for 10min (Figure 22). 
Meanwhile, the protein level of Erk was not altered by the treatment of Aβ1-42 oligomer for 24hr 
(Figure 23). These findings indicate that Aβ1-42 oligomer may not affect Erk activation at the basal 
level or simulated level induced by PDGF-BB and has no impact on Erk protein level within 24hr.  
These findings stand in contrast to other studies that suggest that Aβ1-42 oligomers may affect the 
basal level of Erk activation in a time-dependent manner: in one study conducted by Young and 
colleagues, Aβ1-42 oligomer at 100 nM alone increased Erk1/2 phosphorylation that peaked at 10min 
but declined to basal level after 30-120min in SH-SY5Y cells
124
; in another study performed by Ma 
and colleagues, Aβ1-42 oligomer decreased phosphorylation of Erk2 at 1.5hr and 24hr in SH-SY5Y 
cells and this effect can be reversed by Aβ oligomer-specific antibody
125
. In day 7 hippocampal slice 
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culture, Bell and colleagues observed a slight but significant increase of Erk2 phosphorylation 
induced by oligomeric Aβ1-42 at 100 nM for 5min but the Erk2 phosphorylation became fluctuant 




Since the level of active Erk is not steady but rather fluctuant in response to Aβ1-42 oligomers, it is 
possible that the change of Erk phosphorylation from basal level induced by Aβ1-42 oligomer was 
simply missed in my experiment. For example, in the case of the Aβ acute treatment (Figure 15), 
there was an additional 10min for PDGF-BB after the cells were incubated with Aβ1-42 for 10min and 
therefore when the cells were lysed, they had been exposed to Aβ1-42 for 20min and the level of 
phosphorylated Erk1/2 could have returned to the basal level already as indicated in Young’s study. 
The different concentration of Aβ1-42 oligomer being used (5 μM vs. 100 nM) may also contribute to 
the discrepancies. Since it has been postulated that Erk activation may play a role in Aβ oligomer 
induced neurotoxicity
124-127
, it might be worthwhile to conduct a time-course experiment from 5min in 
both SH-SY5Y cells and primary neurons to reveal a clearer picture on how Aβ1-42 oligomers may 
affect the basal level of Erk phosphorylation. 
To continue the research conducted in this project that aimed to discover the effect of Aβ oligomers 
on the signaling pathways induced by PDGF and other neurotrophic factors in the future, there are 
many other studies should be done than testing Erk phosphorylation alone. For example, a screening 
on other phosphorylation sites on PDGF receptors can be done quickly. This simple and fast 
experiment will provide a clearer picture on how PDGF receptor activation being affected by Aβ 
oligomers and what specific phosphorylation sites are affected. From there, the corresponding 
pathways can be examined more specifically. One pathway that might worth special attention is 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway since it has been strongly implicated in Aβ 
oligomer induced toxicity
108, 128





as well as PDGF neuroprotection
20, 22, 131
. Furthermore, other neurotrophic factors that have been 
strongly implicated in Alzheimer’s disease should be tested. For example, nerve growth factor (NGF) 
family NTFs, including NTF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NF-3) and 
neurotrophin-4/5 (NF-4/5) have been studied most intensively in AD related research
114, 117, 132
 and 
NGF has been used in clinic trial to treat Alzheimer’s disease
133
. Thus, a similar study as in this 
project using NGF or BDNF may be able to reveal if Aβ1-42 oligomer also has a strong negative 
impact on neuronal regeneration process induced by these factors; if it is true, the result will shed 
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Figure 20: Aβ1-42 oligomer treatment for 24hr didn’t affect Erk phosphorylation at both basal and 
stimulated level (Aβ1-42 and PDGF-BB co-treatment).  SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 
μM for 24hr in the presence or absence of PDGF-BB at 10 ng/ml. Western blot membranes were probed with 
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Figure 21: Aβ1-42 oligomer treatment for 24hr didn’t affect Erk phosphorylation at both basal and 
stimulated level (PDGF-BB 10min stimulation). SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 μM for 
24hr before stimulated by PDGF-BB at 10 ng/ml for 10min. Western blot membranes were probed with 
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Figure 22: Aβ1-42 oligomer acute treatment for 10min didn’t affect Erk phosphorylation at both basal and 
stimulated level (PDGF-BB 10min stimulation). SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 μM for 
10min before stimulated by PDGF-BB at 10 ng/ml for 10min. Western blot membranes were probed with 
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Figure 23: Aβ1-42 oligomer treatment for 24hr didn’t affect Erk expression (Aβ1-42 and PDGF-BB co-
treatment). SH-SY5Y cells were exposed to Aβ1-42 oligomer at 5 μM for 24hr in the presence or absence of 
PDGF-BB at 10 ng/ml. Western blot membranes were probed with Erk antibody, stripped, and re-probed with 




Chapter III  
Materials and Methods 
 
3.1. Aβ1-42 oligomer preparation 
This is a modified version of Stine’s protocol
67
. Briefly, Aβ1-42 (rPeptide, Georgia, USA) was 
dissolved in 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (Sigma) to 1 mg/ml solution and 
aliquoted. HFIP was allowed to evaporate in a chemical fume hood until no visible liquid was left in 
the tube.  The resulting peptide film was dried under vacuum for 1hr and stored in a glass desiccator 
at -20°C. Immediately prior to use, the film was re-suspended to 5 mM in DMSO with 10min 
sonication at room temperature, diluted into 100 µM in DMEM/F12 serum and phenol red free 
medium and incubated at 4°C for 24hr. 
3.2. SH-SY5Y cell culturing 
The SH-SY5Y human neuroblastoma cell line is a generous gift from Dr. Shilpa Buch and colleagues 
(University of Nebraska Medical Center, USA). The cells were maintained in DMEM/F-12 (1:1) with 
L-glutamine and HEPES (Fisher) supplemented with 10% fetal bovine serum (FBS) (Sigma) in a 
humid atmosphere of 5% CO2 at 37°C. Prior to treatment with reagents, cells were serum starved for 
24hr by using the same medium without supplementation of FBS.  For MTT assay, the same medium 
without phenol red (Fisher) was used for the serum starvation. 
3.3. Primary neuronal cell culturing 
Primary neuronal cell cultures were produced from hippocampi of 17-day mouse embryos (E17). 
Animal care and treatment were in accordance with institutional guidelines. The time-pregnant mouse 
(E17) was sacrificed by cervical dislocation. The fetuses were then removed and placed in cold 
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dissection medium (15 mL HEPES, 500 mL HBSS, 2.5 g glucose (0.6%), 10 g sucrose (2%), pH 7.4, 
320-335 mOsm/kg). The hippocampi were separated from the brains under a microscope and digested 
in 0.25% trypsin/0.1% EDTA for 30min at 37°C.  Following the removal of the trypsin/EDTA, the 
cells were rinsed with 1 ml plating medium (DMEM-high glucose, supplemented with 10% FBS, 
10% horse serum) (Sigma) for two times and homogenized into 1 ml plating medium by trituration 
using a pipette.  The resulting cell mixture was filtered through a cell strainer (BD) and diluted into 
1/10 hippocampus per ml of plating medium. Cells were counted and plated on poly-D-lysine (Sigma) 
coated 96-well plates in plating medium and grown at 37°C in a humidified atmosphere containing 
5% CO2. After 2-4hr or until cell attachment is established, 50 μl of the plating medium was 
exchanged to feeding medium (serum-free B-27 supplemented Neurobasal medium (Invitrogen) with 
1% penicillin/streptomycin (Fisher)) in each well. Three days after plating, FUDR (0.081 mM 5-
fluoro-2-deoxyuridine and 0.2 mM uridine in DMEM-high glucose) (sigma), a mitotic inhibitor, was 
added to inhibit the growth of non-neuronal cells. After 24hr of FUDR treatment, 30 μl of the 
medium was exchanged for 30 μl of fresh feeding medium and this same medium change strategy 
was applied for all the medium change thereafter. Treatment with reagents was performed 5 or 10 
days after plating. Medium was changed on day 6 and day 9 for the plates treated on day 10. 
3.4. MTT assay 
Cell viability was measured by quantitative colorimetric assay with MTT (3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide), showing the MTT reduction by viable cells as described in 
published literatures
65, 134
. MTT (Sigma) stock solution (5 mg/ml) was prepared by dissolving MTT 
into phosphate buffered saline (PBS). The solution was filtered, aliquoted and stored at -20°C in 
amber microcentrifuge tubes. Each experimental condition was added to 3 wells of the 96-well plates. 
After treatment, the MTT stock solution at a volume of 10% of the medium volume was added per 
well and incubated for 3hr. The resulting formazan crystals were dissolved by adding an amount of 
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MTT solubilization solution (10% Triton X-100 and 0.1 N HCl in anhydrous isopropanol) (Sigma) 
equal to the total volume of original medium followed by trituration. Absorbance was measured at 
570nm and subtracted by background absorbance at 690nm. For each wavelength, a blank was used. 
Cell viability was expressed as percentage of absorbance relative to the cells treated with vehicle. 
3.5. Western blotting 
After treatment with reagents, cells were washed with chilled PBS, and lysed in chilled lysis buffer 
(20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 30 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, and 1% triton-X; 
supplemented with Halt Protease and Phosphatase Inhibitor (Fisher) prior to use). Cells were scraped, 
homogenized and centrifuged at 13,000 x g for 20min at 4°C and the supernatant was collected. 
Homogenates were subjected to SDS-PAGE and proteins were transferred to nitrocellulose 
membranes, blocked with 5% non-fat dry milk in Tris-buffered saline and 0.1% Tween-20 (TBST) 
for 1hr at room temperature or overnight at 4°C, and incubated in primary antibodies for 1hr at room 
temperature or overnight at 4°C.  Membranes were washed three times in TBST, incubated with 
HRP-conjugated secondary antibodies for 1hr at room temperature, washed again, and bound 
antibodies were visualized by enhanced chemiluminescence using chemiluminescent substrate 
Luminata Crescendo HRP (Fisher). Images of Western blots were taken on a Kodak 4000MM Pro 
Imaging Station, and densitometric analyses were performed using Kodak Molecular Imaging 
software. Membranes were then stripped and re-probed with other antibodies. Primary antibodies 
used include those raised against PDGF β-receptor (Santa Cruz), phospho-PDGF β-receptor at Tyr 




Chapter IV  
Conclusions 
 
The optimization steps taken at the beginning in this project provided a solid methodological 
foundation for generating reproducible data in this project as well as to establish this technique in the 
lab for future experimentation. The optimized Aβ1-42 oligomer preparation and the established four-
day MTT assay routine in this project were proven to result in consistent results in both SH-SY5Y 
cells and primary neurons. These optimized procedures can be applied in many other studies testing 
neuroprotective agents against Aβ oligomer toxicities in SH-SY5Y cells and primary neurons. 
Aβ1-42 oligomer elicited a dose-dependent toxicity with a sign of saturation at the higher dosages in 
both SH-SY5Y cells and primary neurons as measured by MTT assay. The saturation suggested a 
possible Aβ-receptor binding mechanism behind Aβ1-42 oligomer induced toxicity. Additional assays 
that test other aspects of Aβ toxicity should be used to describe Aβ oligomer toxicity in a more 
comprehensive way in the future. 
PDGF-BB showed a slight to no neuroprotective effects against Aβ1-42 oligomer induced toxicity in 
MTT assay for both SH-SY5Y cells and primary neurons and NR2B-containing NMDA receptor was 
not involved. The limitation of the MTT assay, the cancerous nature of SH-SY5Y cell line and the 
usage of the specific NMDA receptor antagonist may contribute to the unexpected results. Using 
additional assays to corroborate the MTT assay results, applying broader spectrum NMDA receptor 
antagonists, testing the involvement of NMDA receptors in primary neurons and examining the 
synaptic dysfunction caused by Aβ oligomer in the future may provide a clearer picture on the 




MTT assay in SH-SY5Y cells using c-Abl inhibitor showed that c-Abl was neither promoting nor 
inhibiting PDGF-BB’s neuroprotective effects against Aβ1-42 oligomer induced cytotoxicity. The 
discrepancy compared to previous reported role of c-Abl may be explained by the usage of different 
inhibitors, the distinct features of Aβ oligomers, and the limitations of the MTT assay.   
The inhibitory effects of Aβ1-42 oligomer on PDGF-BB induced mitogenesis observed in MTT assay 
for both SH-SY5Y cells and primary neurons not only explained the poor neuroprotective effect 
elicited by PDGF-BB against Aβ1-42 oligomer but also led to a novel hypothesis that Aβ oligomers 
may elicit neurotoxicity through inhibition on neurotrophic factor induced neuronal regeneration 
pathways.  
This novel hypothesis was supported by results from Western blotting analysis: PDGF-BB induced 
PDGF β-receptor phosphorylation at Tyr1021 can be potently suppressed by Aβ1-42 oligomer both 
acutely and in 24hr. Further Western blotting analyses on PDGF β-receptor levels, Erk 
phosphorylation and expression suggested that Aβ1-42 oligomer may only partially inhibit PDGF β-
receptor activation and its downstream pathways. Future investigation on other phosphorylation sites 
of PDGF receptor and other signaling pathways downstream of PDGF receptor activation will 
provide a clearer picture on how Aβ oligomers affect PDGF receptor signaling. Besides, the same 
strategies developed in this study can also be used to examine the effect of Aβ oligomers on other 
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